[New Year's Message] Jeon Seung-ho, CEO of Daewoong Pharmaceutical, "Accelerating Leap to Global Big Pharma with Innovative New Drug Achievements"
[Asia Economy Reporter Chunhee Lee] Jeon Seung-ho, CEO of Daewoong Pharmaceutical, expressed his determination to become a world-leading global healthcare group based on this year’s innovative new drug development achievements in his New Year's address.
In the New Year's ceremony held online on the morning of the 3rd, CEO Jeon stated in his address, "In 2021, despite the challenging environment due to COVID-19, we achieved meaningful results by maintaining membership in the 1 trillion KRW sales club through the performance of each business sector including ethical drugs (ETC), over-the-counter drugs (OTC), and Nabota, while also achieving the highest operating profit in the company's history. This year, amid the continuously changing environment caused by COVID-19, it is time to concentrate the company’s innovation power to achieve Daewoong Pharmaceutical’s ‘Global 2025 Vision’ and sustain sales growth."
As Daewoong Pharmaceutical’s management policy for 2022, CEO Jeon presented ▲ enhancing customer value ▲ fostering talent that leads change ▲ performance innovation through open collaboration ▲ creating value from global innovative new drugs. He said, “We must always align with our customers’ perspectives to become a company that provides greater value,” and added, “Let us enhance customer value across all areas from disease prevention, treatment, to post-care through new technology development and integration of various platforms.” He also emphasized, “Employee growth is equally important,” stating, “As long as there is passion and willingness to solve problems, even if a great wave of change comes, we can overcome it with innovation and creativity as our weapons.”
Furthermore, he stressed, “We will strengthen our capabilities to establish Daewoong as a global player through continuous open collaboration and accelerate our leap as a global big pharma by realizing innovative new drug achievements in various fields such as the gastroesophageal reflux disease new drug ‘Pexuclu Tab’ scheduled for release in the first half of the year, the diabetes new drug ‘Inavogliflozin,’ as well as new drugs for pulmonary fibrosis and autoimmune diseases.”
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Finally, CEO Jeon encouraged employees by asking them to participate in building the best company with a sense of ownership based on growth and autonomy, saying, “If we continuously develop through relentless challenges and innovation toward higher goals and a brighter future, we will firmly establish ourselves as a global healthcare group representing Korea even in the fiercely competitive global market.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
